For Healthcare Professionals Outside the US
For Healthcare Professionals Outside the US
Progression-free survival (PFS) in patients with a PIK3CA mutation (investigator assessment)
Overall survival in patients with a PIK3CA mutation
Overall response rate in patients with a PIK3CA mutation
Clinical benefit rate in patients with a PIK3CA mutation
Safety
Health-related quality-of-life (HRQOL)
Characteristica |
PIQRAY + fulvestrant (n=169)b |
Plabeco + fulvestrant (n=172)c |
---|---|---|
Line of advanced anticancer treatmentd | ||
First line | 88 (52.1) | 89 (51.7) |
Second line | 79 (46.7) | 82 (47.7) |
Median age, years (range) | 63 (25-87) | 64 (38-92) |
Race | ||
Caucasian | 117 (69.2) | 109 (63.4) |
Asian | 34 (20.1) | 40 (23.3) |
Other/unknown | 18 (10.7) | 23 (13.4) |
ECOG performance status | ||
0 | 112 (66.3) | 113 (65.7) |
1 | 56 (33.1) | 58 (33.7) |
Metastatic sites | ||
Visceral disease | 93 (55.0) | 100 (58.1) |
Lung metastasis | 57 (33.7) | 68 (39.5) |
Liver metastasis | 49 (29.0) | 54 (31.4) |
Bone-only disease | 42 (24.9) | 35 (20.3) |
Prior chemotherapy | ||
Neoadjuvant | 25 (14.8) | 29 (16.9) |
Adjuvant | 78 (46.2) | 86 (50.0) |
Prior CDK4/6 inhibitor treatment | 9 (5.3) | 11 (6.4) |